Enzymerx Announces Strong Phase 1 Results For Pegsitacase
Posted by admin | Posted in Uncategorized | Posted on 25-01-2012-05-2008
0
April 29, 2010. EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome…
Original post: EnzymeRx Announces Strong Phase 1 Results For Pegsitacase